| Year |
Citation |
Score |
| 2024 |
Kang W, Frouni I, Kwan C, Desbiens L, Hamadjida A, Huot P. Activation of mGlu 2/3 receptors with the orthosteric agonist LY-404,039 alleviates dyskinesia in experimental parkinsonism. Behavioural Pharmacology. PMID 38563661 DOI: 10.1097/FBP.0000000000000765 |
0.469 |
|
| 2023 |
Frouni I, Kwan C, Bédard D, Kang W, Hamadjida A, Nuara SG, Gourdon JC, Huot P. Effect of the mGlu positive allosteric modulator ADX-88178 on parkinsonism, psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset. Psychopharmacology. PMID 37516708 DOI: 10.1007/s00213-023-06428-1 |
0.445 |
|
| 2023 |
Kwan C, Frouni I, Bédard D, Hamadjida A, Nuara SG, Gourdon JC, Huot P. The 5-HT inverse agonist nelotanserin alleviates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset. The European Journal of Neuroscience. PMID 37515363 DOI: 10.1111/ejn.16104 |
0.483 |
|
| 2023 |
Kang W, Nuara SG, Bédard D, Frouni I, Kwan C, Hamadjida A, Gourdon JC, Gaudette F, Beaudry F, Huot P. The mGluR orthosteric agonist LY-404,039 reduces dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset. Naunyn-Schmiedeberg's Archives of Pharmacology. PMID 37410156 DOI: 10.1007/s00210-023-02587-2 |
0.484 |
|
| 2023 |
Al-Kassmy J, Sun C, Huot P. 5-HT agonists for levodopa-induced dyskinesia in Parkinson's disease. Neurodegenerative Disease Management. 13: 101-112. PMID 37140165 DOI: 10.2217/nmt-2022-0039 |
0.376 |
|
| 2022 |
Kwan C, Kang W, Kim E, Belliveau S, Frouni I, Huot P. Metabotropic glutamate receptors in Parkinson's disease. International Review of Neurobiology. 168: 1-31. PMID 36868628 DOI: 10.1016/bs.irn.2022.10.001 |
0.364 |
|
| 2022 |
Frouni I, Kwan C, Belliveau S, Hamadjida A, Bédard D, Nuara SG, Gourdon JC, Huot P. Anti-parkinsonian effect of the mGlu positive allosteric modulator LY-487,379 as monotherapy and adjunct to a low L-DOPA dose in the MPTP-lesioned marmoset. European Journal of Pharmacology. 939: 175429. PMID 36502960 DOI: 10.1016/j.ejphar.2022.175429 |
0.379 |
|
| 2022 |
Frouni I, Kang W, Bédard D, Belliveau S, Kwan C, Hadj-Youssef S, Bourgeois-Cayer É, Ohlund L, Sleno L, Hamadjida A, Huot P. Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat. European Journal of Pharmacology. 175090. PMID 35780824 DOI: 10.1016/j.ejphar.2022.175090 |
0.494 |
|
| 2021 |
Kwan C, Lévesque C, Bédard D, Frouni I, Yesuf JM, Hamadjida A, Lévesque D, Clarke PB, Huot P. Autoradiographic labelling of 5-HT receptors in the hemi-parkinsonian rat brain. Neuroscience Research. PMID 34954302 DOI: 10.1016/j.neures.2021.12.004 |
0.394 |
|
| 2021 |
Nuara SG, Gourdon JC, Maddaford S, Huot P. Additive effects of mGluR positive allosteric modulation, mGluR orthosteric stimulation and 5-HTR antagonism on dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset. Naunyn-Schmiedeberg's Archives of Pharmacology. PMID 34550406 DOI: 10.1007/s00210-021-02162-7 |
0.322 |
|
| 2021 |
Frouni I, Belliveau S, Maddaford S, Nuara SG, Gourdon JC, Huot P. Effect of the glycine transporter 1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset. European Journal of Pharmacology. 910: 174452. PMID 34480885 DOI: 10.1016/j.ejphar.2021.174452 |
0.478 |
|
| 2021 |
Kwan C, Nuara SG, Gourdon JC, Huot P. Further characterisation of psychosis-like behaviours induced by L-DOPA in the MPTP-lesioned marmoset. Naunyn-Schmiedeberg's Archives of Pharmacology. PMID 33963876 DOI: 10.1007/s00210-021-02090-6 |
0.426 |
|
| 2021 |
Kwan C, Frouni I, Nuara SG, Belliveau S, Kang W, Hamadjida A, Bédard D, Beaudry F, Panisset M, Gourdon JC, Huot P. Combined 5-HT and mGlu modulation for the treatment of dyskinesia and psychosis in Parkinson's disease. Neuropharmacology. 108465. PMID 33485945 DOI: 10.1016/j.neuropharm.2021.108465 |
0.413 |
|
| 2021 |
Kwan C, Frouni I, Bédard D, Hamadjida A, Huot P. Granisetron, a selective 5-HT3 antagonist, reduces L-3,4-dihydroxyphenylalanine-induced abnormal involuntary movements in the 6-hydroxydopamine-lesioned rat. Behavioural Pharmacology. 32: 43-53. PMID 33399295 DOI: 10.1097/FBP.0000000000000601 |
0.451 |
|
| 2021 |
Frouni I, Kwan C, Nuara SG, Belliveau S, Kang W, Hamadjida A, Bédard D, Gourdon JC, Huot P. Effect of the mGlu positive allosteric modulator CBiPES on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset. Journal of Neural Transmission (Vienna, Austria : 1996). PMID 33392826 DOI: 10.1007/s00702-020-02287-8 |
0.461 |
|
| 2020 |
Kwan C, Nuara SG, Bédard D, Gaudette F, Gourdon JC, Beaudry F, Huot P. Selective blockade of the 5-HT receptor acutely alleviates dyskinesia and psychosis in the parkinsonian marmoset. Neuropharmacology. 108386. PMID 33152452 DOI: 10.1016/j.neuropharm.2020.108386 |
0.515 |
|
| 2020 |
Hamadjida A, Nuara SG, Kwan C, Frouni I, Bédard D, Gourdon JC, Huot P. Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset. Naunyn-Schmiedeberg's Archives of Pharmacology. PMID 32621059 DOI: 10.1007/S00210-020-01933-Y |
0.563 |
|
| 2020 |
Hamadjida A, Nuara SG, Frouni I, Kwan C, Bédard D, Gourdon JC, Huot P. Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmoset. Naunyn-Schmiedeberg's Archives of Pharmacology. PMID 32601846 DOI: 10.1007/S00210-020-01927-W |
0.514 |
|
| 2020 |
Nuara SG, Hamadjida A, Gourdon JC, Huot P. The mGlu antagonist LY-341,495 reverses the anti-dyskinetic and anti-psychotic effects of the mGlu activators LY-487,379 and LY-354,740 in the MPTP-lesioned marmoset. Journal of Neural Transmission (Vienna, Austria : 1996). PMID 32333122 DOI: 10.1007/s00702-020-02196-w |
0.428 |
|
| 2020 |
Nuara SG, Hamadjida A, Kwan C, Bédard D, Frouni I, Gourdon JC, Huot P. Combined mGlu orthosteric stimulation and positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the parkinsonian marmoset. Journal of Neural Transmission (Vienna, Austria : 1996). PMID 32246204 DOI: 10.1007/s00702-020-02185-z |
0.485 |
|
| 2020 |
Sid-Otmane L, Huot P, Panisset M. Effect of Antidepressants on Psychotic Symptoms in Parkinson Disease: A Review of Case Reports and Case Series. Clinical Neuropharmacology. PMID 32217864 DOI: 10.1097/Wnf.0000000000000384 |
0.385 |
|
| 2020 |
Kwan C, Bedard D, Frouni I, Gaudette F, Beaudry F, Hamadjida A, Huot P. Pharmacokinetic profile of the selective 5-HT3 receptor antagonist ondansetron in the rat: an original study and a mini-review of the behavioural pharmacological literature in the rat. Canadian Journal of Physiology and Pharmacology. PMID 32017606 DOI: 10.1139/Cjpp-2019-0551 |
0.335 |
|
| 2020 |
Sid-Otmane L, Hamadjida A, Nuara SG, Bédard D, Gaudette F, Gourdon JC, Michaud V, Beaudry F, Panisset M, Huot P. Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset. European Journal of Pharmacology. 172957. PMID 32004527 DOI: 10.1016/J.Ejphar.2020.172957 |
0.553 |
|
| 2020 |
Hamadjida A, Sid-Otmane L, Kwan C, Frouni I, Nafade V, Bédard D, Gagnon D, Wallman MJ, Rouillard C, Parent A, Parent M, Huot P. The highly-selective mGlu receptor positive allosteric modulator, LY-487,379 alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease. The European Journal of Neuroscience. PMID 31944461 DOI: 10.1111/Ejn.14679 |
0.534 |
|
| 2020 |
Kwan C, Frouni I, Bédard D, Hamadjida A, Huot P. Ondansetron, a highly selective 5-HT receptor antagonist, reduces L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease. European Journal of Pharmacology. 172914. PMID 31926127 DOI: 10.1016/J.Ejphar.2020.172914 |
0.557 |
|
| 2019 |
Frouni I, Hamadjida A, Kwan C, Bédard D, Nafade V, Gaudette F, Nuara SG, Gourdon JC, Beaudry F, Huot P. Activation of mGlu receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism. Neuropharmacology. 158: 107725. PMID 31351976 DOI: 10.1016/J.Neuropharm.2019.107725 |
0.5 |
|
| 2018 |
Kwan C, Frouni I, Bédard D, Nuara SG, Gourdon JC, Hamadjida A, Huot P. 5-HT blockade for dyskinesia and psychosis in Parkinson's disease: is there a limit to the efficacy of this approach? A study in the MPTP-lesioned marmoset and a literature mini-review. Experimental Brain Research. PMID 30443669 DOI: 10.1007/S00221-018-5434-9 |
0.573 |
|
| 2018 |
Frouni I, Kwan C, Bédard D, Belliveau S, Bourgeois-Cayer É, Gaudette F, Beaudry F, Hamadjida A, Huot P. Effect of the selective 5-HT receptor antagonist EMD-281,014 on L-DOPA-induced abnormal involuntary movements in the 6-OHDA-lesioned rat. Experimental Brain Research. PMID 30298296 DOI: 10.1007/S00221-018-5390-4 |
0.576 |
|
| 2018 |
Hamadjida A, Frouni I, Kwan C, Huot P. Classic animal models of Parkinson's disease: a historical perspective. Behavioural Pharmacology. PMID 30216234 DOI: 10.1097/FBP.0000000000000441 |
0.328 |
|
| 2018 |
Hamadjida A, Nuara SG, Bédard D, Frouni I, Kwan C, Gourdon JC, Huot P. Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset. Naunyn-Schmiedeberg's Archives of Pharmacology. PMID 30088028 DOI: 10.1007/S00210-018-1549-6 |
0.575 |
|
| 2018 |
Gaudette F, Hamadjida A, Bédard D, Nuara SG, Gourdon JC, Michaud V, Beaudry F, Huot P. Development of a selective and sensitive high-performance liquid chromatography-tandem mass spectrometry assay to support pharmacokinetic studies of LY-487,379 in rat and marmoset. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1093: 1-7. PMID 29980099 DOI: 10.1016/J.Jchromb.2018.06.036 |
0.303 |
|
| 2018 |
Hamadjida A, Nuara SG, Bedard D, Gaudette F, Beaudry F, Gourdon JC, Huot P. The highly selective 5-HT antagonist EMD-281,014 reduces dyskinesia and psychosis in the L-DOPA-treated parkinsonian marmoset. Neuropharmacology. PMID 29969592 DOI: 10.1016/J.Neuropharm.2018.06.038 |
0.535 |
|
| 2017 |
Hamadjida A, Nuara SG, Gourdon JC, Huot P. Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease. Journal of Neural Transmission (Vienna, Austria : 1996). PMID 29247391 DOI: 10.1007/S00702-017-1830-8 |
0.567 |
|
| 2017 |
Hamadjida A, Nuara SG, Gourdon JC, Huot P. The effect of mianserin on the severity of psychosis and dyskinesia in the parkinsonian marmoset. Progress in Neuro-Psychopharmacology & Biological Psychiatry. PMID 28882428 DOI: 10.1016/J.Pnpbp.2017.09.001 |
0.567 |
|
| 2017 |
Huot P, Sgambato-Faure V, Fox SH, McCreary AC. Serotonergic approaches in Parkinson's disease: translational perspectives, an update. Acs Chemical Neuroscience. PMID 28460160 DOI: 10.1021/Acschemneuro.6B00440 |
0.494 |
|
| 2017 |
Hamadjida A, Nuara SG, Veyres N, Frouni I, Kwan C, Sid-Otmane L, Harraka MJ, Gourdon JC, Huot P. The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset. Psychopharmacology. PMID 28130646 DOI: 10.1007/S00213-017-4530-Z |
0.464 |
|
| 2016 |
Huot P, Fox SH, Brotchie JM. Dopamine Reuptake Inhibitors in Parkinson's Disease: A Review of Nonhuman Primate Studies and Clinical Trials. The Journal of Pharmacology and Experimental Therapeutics. 357: 562-9. PMID 27190169 DOI: 10.1124/Jpet.116.232371 |
0.528 |
|
| 2016 |
Huynh NT, Sid-Otmane L, Panisset M, Huot P. A Man With Persistent Dopamine Agonist Withdrawal Syndrome After 7 Years Being Off Dopamine Agonists. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 1-2. PMID 26842385 DOI: 10.1017/Cjn.2015.389 |
0.324 |
|
| 2015 |
Pourcher E, Huot P. Adenosine 2A Receptor Antagonists for the Treatment of Motor Symptoms in Parkinson's Disease. Movement Disorders Clinical Practice. 2: 331-340. PMID 30363540 DOI: 10.1002/Mdc3.12187 |
0.494 |
|
| 2015 |
Huot P. The pons and human affective processing - Implications for Parkinson's disease. Ebiomedicine. 2: 1592-3. PMID 26870780 DOI: 10.1016/J.Ebiom.2015.10.031 |
0.357 |
|
| 2015 |
Huot P, Hutchison WD. Serotonin/dopamine transporter ratio as a predictor of l-dopa-induced dyskinesia. Neurology. 85: 840-1. PMID 26253446 DOI: 10.1212/WNL.0000000000001915 |
0.431 |
|
| 2015 |
Huot P, Johnston TH, Fox SH, Newman-Tancredi A, Brotchie JM. The highly-selective 5-HT1A agonist F15599 reduces l-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque. Neuropharmacology. 97: 306-11. PMID 26071982 DOI: 10.1016/J.Neuropharm.2015.05.033 |
0.517 |
|
| 2015 |
Huot P, Fox SH, Brotchie JM. Monoamine reuptake inhibitors in Parkinson's disease. Parkinson's Disease. 2015: 609428. PMID 25810948 DOI: 10.1155/2015/609428 |
0.522 |
|
| 2015 |
Huot P. L-DOPA-induced dyskinesia, is striatal dopamine depletion a requisite? Journal of the Neurological Sciences. 351: 9-12. PMID 25758471 DOI: 10.1016/J.Jns.2015.02.041 |
0.54 |
|
| 2015 |
Huot P, Johnston TH, Fox SH, Brotchie JM. Pioglitazone may impair L-DOPA anti-parkinsonian efficacy in the MPTP-lesioned macaque: results of a pilot study. Synapse (New York, N.Y.). 69: 99-102. PMID 25559284 DOI: 10.1002/Syn.21801 |
0.503 |
|
| 2015 |
Huot P, Johnston TH, Koprich JB, Espinosa MC, Reyes MG, Fox SH, Brotchie JM. L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat. Behavioural Pharmacology. 26: 101-8. PMID 25303957 DOI: 10.1097/Fbp.0000000000000096 |
0.503 |
|
| 2014 |
Huynh NT, Huot P. A woman with functional tremor treated with L-DOPA for 14 years. Journal of the Neurological Sciences. 346: 358-9. PMID 25218418 DOI: 10.1016/J.Jns.2014.08.045 |
0.398 |
|
| 2014 |
Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ, Brotchie JM. UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset. Neuropharmacology. 82: 76-87. PMID 24447715 DOI: 10.1016/J.Neuropharm.2014.01.012 |
0.553 |
|
| 2014 |
Huynh NT, Huot P. Therapies under investigation for treating Parkinson's disease psychosis Clinical Investigation. 4: 889-901. DOI: 10.4155/Cli.14.84 |
0.411 |
|
| 2013 |
Huot P, Fox SH. The serotonergic system in motor and non-motor manifestations of Parkinson's disease. Experimental Brain Research. 230: 463-76. PMID 23811734 DOI: 10.1007/S00221-013-3621-2 |
0.522 |
|
| 2013 |
Johnston TH, Huot P, Fox SH, Koprich JB, Szeliga KT, James JW, Graef JD, Letchworth SR, Jordan KG, Hill MP, Brotchie JM. TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque. Neuropharmacology. 73: 337-47. PMID 23770260 DOI: 10.1016/J.Neuropharm.2013.06.005 |
0.498 |
|
| 2013 |
Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM. The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease. Pharmacological Reviews. 65: 171-222. PMID 23319549 DOI: 10.1124/Pr.111.005678 |
0.499 |
|
| 2013 |
Koprich JB, Huot P, Fox SH, Jarvie K, Lang AE, Seeman P, Brotchie JM. The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 43: 151-6. PMID 23306217 DOI: 10.1016/J.Pnpbp.2012.12.008 |
0.513 |
|
| 2013 |
Huot P, Johnston TH, Snoeren T, Koprich JB, Hill MP, Fox SH, Brotchie JM. Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque. The European Journal of Neuroscience. 37: 831-8. PMID 23281915 DOI: 10.1111/Ejn.12093 |
0.482 |
|
| 2013 |
Johnston TH, Huot P, Damude S, Fox SH, Jones SW, Rusche JR, Brotchie JM. RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study. Parkinsonism & Related Disorders. 19: 260-4. PMID 22901956 DOI: 10.1016/J.Parkreldis.2012.07.001 |
0.509 |
|
| 2012 |
Huot P, Johnston TH, Gandy MN, Reyes MG, Fox SH, Piggott MJ, Brotchie JM. The monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmoset. Plos One. 7: e45587. PMID 23029119 DOI: 10.1371/Journal.Pone.0045587 |
0.531 |
|
| 2012 |
Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM. L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease. Neuropharmacology. 63: 829-36. PMID 22722022 DOI: 10.1016/J.Neuropharm.2012.06.012 |
0.515 |
|
| 2012 |
Huot P, Johnston TH, Koprich JB, Aman A, Fox SH, Brotchie JM. L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. The Journal of Pharmacology and Experimental Therapeutics. 342: 576-85. PMID 22619253 DOI: 10.1124/Jpet.112.195693 |
0.547 |
|
| 2012 |
Huot P, Johnston TH, Visanji NP, Darr T, Pires D, Hazrati LN, Brotchie JM, Fox SH. Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 27: 735-42. PMID 22419526 DOI: 10.1002/Mds.24964 |
0.427 |
|
| 2012 |
Johnston TH, Millar Z, Huot P, Wagg K, Thiele S, Salomonczyk D, Yong-Kee CJ, Gandy MN, McIldowie M, Lewis KD, Gomez-Ramirez J, Lee J, Fox SH, Martin-Iverson M, Nash JE, et al. A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 26: 2154-63. PMID 22345403 DOI: 10.1096/Fj.11-195016 |
0.5 |
|
| 2012 |
Huot P, Johnston TH, Koprich JB, Winkelmolen L, Fox SH, Brotchie JM. Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque. Neurobiology of Aging. 33: 207.e9-19. PMID 21051107 DOI: 10.1016/J.Neurobiolaging.2010.09.011 |
0.511 |
|
| 2012 |
Huot P, Johnston TH, Winkelmolen L, Fox SH, Brotchie JM. 5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA. Neurobiology of Aging. 33: 194.e5-15. PMID 20561716 DOI: 10.1016/J.Neurobiolaging.2010.04.035 |
0.5 |
|
| 2012 |
Koprich J, Johnston T, Huot P, Brotchie J. 3.118 PRIMATE AND RODENT MODELS OF PARKINSON'S DISEASE BASED ON VIRAL VECTOR MEDIATED OVEREXPRESSION OF ALPHA SYNUCLEIN Parkinsonism & Related Disorders. 18: S193. DOI: 10.1016/S1353-8020(11)70834-3 |
0.307 |
|
| 2012 |
Huot P, Koprich J, Johnston T, Fox S, Brotchie J. 2.217 PHARMACOKINETIC PROFILE OF THE SELECTIVE DOPAMINE D4 RECEPTOR ANTAGONIST L-745,870 IN THE MPTP-LESIONED NON-HUMAN PRIMATE MODEL OF PARKINSON'S DISEASE Parkinsonism & Related Disorders. 18: S119. DOI: 10.1016/S1353-8020(11)70541-7 |
0.475 |
|
| 2011 |
Huot P, Fox SH, Brotchie JM. The serotonergic system in Parkinson's disease. Progress in Neurobiology. 95: 163-212. PMID 21878363 DOI: 10.1016/J.Pneurobio.2011.08.004 |
0.475 |
|
| 2011 |
Huot P, Brotchie JM. 5-HT(1A) receptor stimulation and L-DOPA-induced dyskinesia in Parkinson's disease: bridging the gap between serotonergic and glutamatergic mechanisms. Experimental Neurology. 231: 195-8. PMID 21819982 DOI: 10.1016/J.Expneurol.2011.07.006 |
0.466 |
|
| 2011 |
Huot P, Fox SH, Newman-Tancredi A, Brotchie JM. Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism? The Journal of Pharmacology and Experimental Therapeutics. 339: 2-8. PMID 21784889 DOI: 10.1124/Jpet.111.184093 |
0.431 |
|
| 2011 |
Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ, Brotchie JM. Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 7190-8. PMID 21562283 DOI: 10.1523/Jneurosci.1171-11.2011 |
0.511 |
|
| 2011 |
Koprich JB, Johnston TH, Huot P, Reyes MG, Espinosa M, Brotchie JM. Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein. Plos One. 6: e17698. PMID 21408191 DOI: 10.1371/Journal.Pone.0017698 |
0.42 |
|
| 2011 |
Johnston TH, Huot P, Fox SH, Wakefield JD, Sykes KA, Bartolini WP, Milne GT, Pearson JP, Brotchie JM. Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease. The Journal of Pharmacology and Experimental Therapeutics. 336: 423-30. PMID 20966038 DOI: 10.1124/Jpet.110.169532 |
0.538 |
|
| 2011 |
Huot P, Fox SH. Nondopaminergic treatments for Parkinson’s disease Neurodegenerative Disease Management. 1: 491-512. DOI: 10.2217/Nmt.11.62 |
0.449 |
|
| 2010 |
Huot P, Johnston TH, Darr T, Hazrati LN, Visanji NP, Pires D, Brotchie JM, Fox SH. Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 1399-408. PMID 20629135 DOI: 10.1002/Mds.23083 |
0.44 |
|
| 2010 |
Fox SH, Visanji N, Reyes G, Huot P, Gomez-Ramirez J, Johnston T, Brotchie JM. Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 37: 86-95. PMID 20169779 DOI: 10.1017/S0317167100009707 |
0.435 |
|
| 2008 |
Huot P, Lévesque M, Morissette M, Calon F, Dridi M, Di Paolo T, Parent A. L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys. Journal of Chemical Neuroanatomy. 35: 77-84. PMID 17706922 DOI: 10.1016/J.Jchemneu.2007.06.004 |
0.44 |
|
| 2007 |
Huot P, Parent A. Dopaminergic neurons intrinsic to the striatum. Journal of Neurochemistry. 101: 1441-7. PMID 17286588 DOI: 10.1111/J.1471-4159.2006.04430.X |
0.359 |
|
| 2007 |
Huot P, Lévesque M, Parent A. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea. Brain : a Journal of Neurology. 130: 222-32. PMID 17142832 DOI: 10.1093/Brain/Awl332 |
0.363 |
|
| Show low-probability matches. |